User profiles for JOSEPH GLIGOROV

J Gligorov

Institut Universitaire de Cancérologie AP-HP. Sorbonne Université
Verified email at aphp.fr
Cited by 15160

[HTML][HTML] ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

…, P Francis, K Gelmon, SH Giordano, J Gligorov… - The Breast, 2014 - Elsevier
Author links open overlay panel F. Cardoso a, A. Costa bc, L. Norton d, E. Senkus e, M. Aapro
f, F. André g, CH Barrios h, J. Bergh i, L. Biganzoli j, KL Blackwell k, MJ Cardoso l, T. Cufer …

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆

…, A DeMichele, R Dent, D Fenlon, J Gligorov… - Annals of …, 2021 - annalsofoncology.org
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard-of-…

Preclinical pharmacology of the taxanes: implications of the differences

J Gligorov, JP Lotz - The oncologist, 2004 - academic.oup.com
Joseph Gligorov , Joseph GligorovJoseph Gligorov, Jean Pierre Lotz, Preclinical
Pharmacology of the Taxanes: Implications of the Differences, The Oncologist, Volume 9, Issue S2, …

Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study

V Launay‐Vacher, S Oudard, N Janus, J Gligorov… - Cancer, 2007 - Wiley Online Library
BACKGROUND. The Renal Insufficiency and Cancer Medications (IRMA) study is a French
national observational study. The results from this study of nearly 5000 patients …

[HTML][HTML] First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor …

…, F Cvitkovic, N Bousetta, J Medioni, J Gligorov… - Journal of translational …, 2010 - Springer
Background IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class
II with high avidity and mediates APC and then antigen-experienced memory CD8 + T cell …

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised …

X Pivot, J Gligorov, V Müller, P Barrett-Lee… - The lancet …, 2013 - thelancet.com
Background Subcutaneous trastuzumab has shown non-inferior efficacy and a similar
pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with …

A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–Cancer‐Associated thrombosis study

…, COMPASS–CAT Working Group, J Gligorov… - The …, 2017 - academic.oup.com
Background The stratification of outpatients on chemotherapy for breast, colorectal, lung, and
ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical need. …

[HTML][HTML] Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

…, K Fizazi, V Galibert, L Gladieff, J Gligorov… - European Journal of …, 2021 - Elsevier
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and
are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-…

[HTML][HTML] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …

X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop… - Annals of oncology, 2014 - Elsevier
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …

Efficacy of circulating tumor cell count–driven vs clinician-driven first-line therapy choice in hormone receptor–positive, ERBB2-negative metastatic breast cancer: The …

…, S Ladoire, H Naman, F Dalenc, J Gligorov… - JAMA …, 2021 - jamanetwork.com
Importance The choice between chemotherapy and endocrine therapy as first-line treatment
for hormone receptor–positive, ERBB2 (also known as HER2)-negative metastatic breast …